Cytokeratin 13 (CK13) Expression in Cancer: A Tissue Microarray Study on 10,439 Tumors
Standard
Cytokeratin 13 (CK13) Expression in Cancer: A Tissue Microarray Study on 10,439 Tumors. / Lennartz, Maximilian; Ullmann, Verena Sofia; Gorbokon, Natalia; Uhlig, Ria; Dwertmann Rico, Sebastian; Kind, Simon; Reiswich, Viktor; Viehweger, Florian; Kluth, Martina; Hube-Magg, Claudia; Bernreuther, Christian; Büscheck, Franziska; Putri, Devita; Clauditz, Till S; Fraune, Christoph; Hinsch, Andrea; Jacobsen, Frank; Krech, Till; Lebock, Patrick; Steurer, Stefan; Burandt, Eike; Minner, Sarah; Marx, Andreas H; Simon, Ronald; Sauter, Guido; Menz, Anne.
In: APMIS, Vol. 131, No. 2, 02.2023, p. 77-91.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cytokeratin 13 (CK13) Expression in Cancer: A Tissue Microarray Study on 10,439 Tumors
AU - Lennartz, Maximilian
AU - Ullmann, Verena Sofia
AU - Gorbokon, Natalia
AU - Uhlig, Ria
AU - Dwertmann Rico, Sebastian
AU - Kind, Simon
AU - Reiswich, Viktor
AU - Viehweger, Florian
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Bernreuther, Christian
AU - Büscheck, Franziska
AU - Putri, Devita
AU - Clauditz, Till S
AU - Fraune, Christoph
AU - Hinsch, Andrea
AU - Jacobsen, Frank
AU - Krech, Till
AU - Lebock, Patrick
AU - Steurer, Stefan
AU - Burandt, Eike
AU - Minner, Sarah
AU - Marx, Andreas H
AU - Simon, Ronald
AU - Sauter, Guido
AU - Menz, Anne
N1 - This article is protected by copyright. All rights reserved.
PY - 2023/2
Y1 - 2023/2
N2 - Cytokeratin 13 (CK13) is a type I acidic low molecular weight cytokeratin, which is mainly expressed in urothelium and in the squamous epithelium of various sites of origin. Loss of CK13 has been implicated in the development and progression of squamous epithelial neoplasms. To comprehensively determine CK13 expression in normal and neoplastic tissues, a tissue microarray containing 10,439 samples from 131 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. CK13 immunostaining was detectable in 42 (32.1%) of the 131 tumor categories including 24 (18.3%) tumor types with at least one strongly positive case. The highest rate of positive staining was found in various urothelial neoplasms (52.1-92.3%) including Brenner tumor of the ovary (86.8%) and in squamous cell carcinomas from various sites of origin (39.1-77.6%), Warthin tumors of parotid glands (66.7%), adenosquamous carcinomas of the cervix (33.3%), thymomas (16.0%), and endometroid carcinomas of the ovary (15.3%). Twenty other epithelial or germ cell neoplasms showed - a usually weak - CK13 positivity in less than 15% of the cases. In bladder cancer, reduced CK13 expression was linked to high grade and advanced stage (p < 0.0001 each). In squamous cell carcinoma of the cervix, reduced CK13 immunostaining was related to high grade (p = 0.0295) and shortened recurrence-free (p = 0.0094) and overall survival (p = 0.0274). In a combined analysis of 1,151 squamous cell carcinomas from 11 different sites of origin, reduced CK13 staining was linked to high grade (p = 0.0050). Our data provide a comprehensive overview on CK13 expression in normal and neoplastic human tissues. CK13 expression predominates in urothelial neoplasms and in squamous cell carcinomas of different organs, and a loss of CK13 expression is associated with aggressive disease in these tumors.
AB - Cytokeratin 13 (CK13) is a type I acidic low molecular weight cytokeratin, which is mainly expressed in urothelium and in the squamous epithelium of various sites of origin. Loss of CK13 has been implicated in the development and progression of squamous epithelial neoplasms. To comprehensively determine CK13 expression in normal and neoplastic tissues, a tissue microarray containing 10,439 samples from 131 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. CK13 immunostaining was detectable in 42 (32.1%) of the 131 tumor categories including 24 (18.3%) tumor types with at least one strongly positive case. The highest rate of positive staining was found in various urothelial neoplasms (52.1-92.3%) including Brenner tumor of the ovary (86.8%) and in squamous cell carcinomas from various sites of origin (39.1-77.6%), Warthin tumors of parotid glands (66.7%), adenosquamous carcinomas of the cervix (33.3%), thymomas (16.0%), and endometroid carcinomas of the ovary (15.3%). Twenty other epithelial or germ cell neoplasms showed - a usually weak - CK13 positivity in less than 15% of the cases. In bladder cancer, reduced CK13 expression was linked to high grade and advanced stage (p < 0.0001 each). In squamous cell carcinoma of the cervix, reduced CK13 immunostaining was related to high grade (p = 0.0295) and shortened recurrence-free (p = 0.0094) and overall survival (p = 0.0274). In a combined analysis of 1,151 squamous cell carcinomas from 11 different sites of origin, reduced CK13 staining was linked to high grade (p = 0.0050). Our data provide a comprehensive overview on CK13 expression in normal and neoplastic human tissues. CK13 expression predominates in urothelial neoplasms and in squamous cell carcinomas of different organs, and a loss of CK13 expression is associated with aggressive disease in these tumors.
U2 - 10.1111/apm.13280
DO - 10.1111/apm.13280
M3 - SCORING: Journal article
C2 - 36269681
VL - 131
SP - 77
EP - 91
JO - APMIS
JF - APMIS
SN - 0903-4641
IS - 2
ER -
